SIRT1 and Parkinson disease: We found that after intraperitoneal administration of the two agents at experimental dosage for 7 days, SIRT1 protein level and activity were markedly increased in the PD administration group but significantly decreased in the Ex527 group (P < 0.01 for both groups versus sham, Figure 6).